Trials / Completed
CompletedNCT01720134
The Impact of Legally Enforced Embryo Transfer Policy (Belgian Law 2003) on Cumulative Delivery Rate.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,258 (actual)
- Sponsor
- KU Leuven · Academic / Other
- Sex
- All
- Age
- 18 Years – 43 Years
- Healthy volunteers
- Not accepted
Summary
Multiple pregnancy (MP) is associated with significant fetomaternal complications and a high cost. The multiple pregnancy rate per cycle (MPR) of treatment with Assisted Reproductive Technology (ART) is 25 % or higher even in countries where ART is reimbursed, much higher than the 1% after natural conception, related to the number of embryos transferred, and preventable by single embryo transfer (SET). In Belgium, the laboratory costs for 6 fresh ART cycles are reimbursed for female patients younger than 43 with a Belgian insurance number since July 2003, but only if a limited number of embryos is transferred depending on female age and cycle rank. Although this policy has resulted in a significant reduction in the MPR after ART in Belgium from 24 % to 13 %, available data are cycle based and it is unknown if the cumulative delivery rate per patient is affected by this legislation. The aim of this study was to test the hypothesis that Belgian ART legislation since 2003, coupling lab reimbursement to restriced embryo transfer policy, has resulted in a reduced CDR when compared to the situation before 2003.
Conditions
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2012-06-01
- Completion
- 2012-07-01
- First posted
- 2012-11-02
- Last updated
- 2017-03-30
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT01720134. Inclusion in this directory is not an endorsement.